Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

The Hamner Institutes and Cellular Dynamics Collaborate

Published: Monday, December 09, 2013
Last Updated: Monday, December 09, 2013
Bookmark and Share
The parties will develop predictive in vitro screening assays for chemical, environmental and pharmaceutical toxicology assessments.

Current in vitro models of liver function employ immortalized cell lines, animal models and primary tissue isolates harvested from human cadavers.  Each of these model systems presents limitations in functionality, reproducibility, translatability and availability.  

Human iPS cell-derived hepatocytes could provide a consistent, reproducible and limitless source of liver tissue that reflects native liver function and may offer significant improvement over existing in vitro models.  

CDI will provide iCell® Hepatocytes to The Hamner for use in an on-going program of research, referred to as “Toxicity Testing in the 21st Century: Toxicity Pathways and Network Biology.”  This program employs several prototypical toxicity pathway case studies to develop human cell-based assays that map and model key cell signaling pathways in order to evaluate dose response. These assays, once validated with prototype chemicals, should enable toxicity testing and risk assessments based solely on in vitro test results, without progressing to toxicity studies in intact animals.

These in vitro-based toxicity testing schemes will speed testing of both important compounds in commerce and new compounds coming into use. More rapid testing will also help assess the backlog of thousands of chemicals for which there is very limited toxicity test data. As these test technologies mature, they could also provide a means to speed drug discovery by providing assessments of safety far earlier in the drug development process.

The Hamner toxicity pathway research program is a pre-competitive, multi-organization partnership designed to advance an integrated systems biology approach to toxicity testing research. Partners sponsoring the research include Agilent Technologies Inc., Illumina, Dow Chemical, Dow Corning Corporation, ExxonMobil, Unilever and CropLife America member companies. The Long-Range Research Initiative (LRI) of the American Chemistry Council supported earlier stages of this research.  CDI will join this consortium and will collaborate with Hamner scientists on technical aspects of assay development.  

“The Hamner’s multi-stakeholder toxicity testing program needs a variety of normal cell types for studying chemical toxicity in human cells.  New iPS-cell technologies, spearheaded by CDI, promise to make many stem cell-derived products available to transform in vitro testing.  We are particularly enthusiastic about the use of iCell Hepatocytes to create models of liver toxicity and for evaluating pathways of metabolism,” said Dr. Melvin Andersen, project director at The Hamner. “More broadly, stem cell products enhance work on the whole suite of pathways of interest to our diverse partners.  As other stem cell platforms develop, we can connect them sequentially and examine multi-day treatment for many tissues with realistic exposures. These iCell Hepatocytes and other emerging stem cell-based products provide great value for safety assessments for all our partners.”

Chris Parker, chief commercial officer of CDI, said, “We are excited to be working with The Hamner and this consortium to work toward better predictivity of human response to chemical compounds. Current models miss toxicities that might only manifest themselves in a human cell model, or falsely misidentify toxicities for compounds that would be safe. Published studies have shown numerous examples of our human iPS cell-derived iCell products to be more predictive than comparison current cell models. Through this collaboration we hope to further improve the safety of chemical compounds as well as the efficiency of research studies.”

A report of a recent review of The Hamner program “Toxicity Testing in the 21st Century: Toxicity Pathways and Network Biology” is available at www.thehamner.org/tt21c and provides a synopsis of the first prototype pathways serving as examples of this integrated systems biology approach to toxicity testing. 


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

GE Healthcare and Cellular Dynamics International Agree to Sublicense for Cellular Assay Patents
Companies have announced that GE Healthcare has licensed CDI to develop, manufacture and sell cellular assays and models derived from iPS cells for use in drug discovery and toxicity screening.
Wednesday, December 19, 2012
Cellular Dynamics International and Roche Transition Early Access
Collaboration into a standard supply agreement ahead of schedule.
Saturday, March 26, 2011
CDI, ACEA and Roche Cooperate to Evaluate iCell Cardiomyocytes on the xCELLigence System
The partnership will bring early and accurate prediction of potential cardiotoxic side effects to the drug discovery process.
Tuesday, September 21, 2010
Cellular Dynamics Partners with iPS Academia Japan to In-License Seminal iPS Cell Patent Portfolio
Companies announce a nonexclusive licensing agreement for the seminal iPSC patent portfolio arising out of the work of Dr. Shinya Yamanaka.
Monday, May 10, 2010
Cellular Dynamics Raises $40.6 MM to Revolutionize Pharma Drug Research
The financing enables the company to increase production capacity for its iCell™ Cardiomyocytes and to launch additional human tissue cell products.
Thursday, April 29, 2010
CDI’s iCell™ Cardiomyocytes Named to MIT Technology Review’s Annual 10 Emerging Technologies List
iCell Cardiomyocytes are first human IPSC-derived cell type launched for high throughput drug discovery and toxicity testing.
Friday, April 23, 2010
Cellular Dynamics International In-Licenses Key Patent Portfolio for Using Stem Cell-Derived Cells in Drug Testing
Greater than 90 percent cell type purification enabled through exclusively licensed technology.
Friday, July 17, 2009
Cellular Dynamics International and Roche Expand Existing Cardiotoxicity Screening Agreement
The two-year collaboration aims to enhance drug safety testing in order to bring promising therapies to patients.
Thursday, July 02, 2009
Cellular Dynamics International Licenses Key Patent Portfolio Surrounding Cardiovascular Progenitor Cells
The exclusive license covers differentiation of stem cells into all cell types of the human heart.
Wednesday, June 03, 2009
Scientific News
Novel Technique for Kidney Research Developed
To better understand how the treatment leads to kidney damage, and possibly prevent it, a team of researchers at Yale School of Medicine developed a new 3D-imaging technique to peer deep into these vital organs.
Microscopic Fish are 3D-Printed to do More Than Swim
Researchers demonstrate a novel method to build microscopic robots with complex shapes and functionalities.
Promising Class of New Cancer Drugs Cause Memory Loss in Mice
New findings from The Rockefeller University suggest that the original version of BET inhibitors causes molecular changes in mouse neurons, and can lead to memory loss in mice that receive it.
A Better Way to Personalize Bladder Cancer Treatments
Researchers at UC Davis, in collaboration with colleagues at Jackson Laboratory, have developed a new way to personalize treatments for aggressive bladder cancer.
Breath of Fresh Air for Asthmatics
Researchers hope to develop a platform that will allow a range of drugs to be delivered by inhalation.
Capturing Cell Growth in 3-D
Spinout’s microfluidics device better models how cancer and other cells interact in the body.
Elastic Patch Releases Drugs in a Stretch
Researchers from have developed a drug delivery technology that consists of an elastic patch that can be applied to the skin and will release drugs whenever the patch is stretched.
New Extra ‘Sticky’ Microgel Could Revolutionise Bladder Cancer Treatment
Researchers have designed a new super-efficient way of delivering an anti-cancer drug which could extend and improve the quality of life for bladder cancer patients - and perhaps save lives.
Liposomes: A Basis for Drugs of the Future
An international group of scientists have recently presented a review of liposomes, microscopic capsules widely used all over the world in the development of new drugs.
Common Medications Could Delay Brain Injury Recovery
Drugs used to treat common complaints could delay the recovery of brain injury patients according to research by University of East Anglia (UEA) and University of Aberdeen scientists, published today in Brain Injury.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!